Modulation of the insulin-like growth factorml system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines
1998

Effects of 4-HPR on Breast Cancer Cell Lines

publication Evidence: moderate

Author Information

Author(s): RE Favoni, A de Cupis, S Bruno, D Yee, A Ferrera, P Piranil, A Costa, A Decensi

Primary Institution: National Institute for Cancer Research

Hypothesis

Does N-(4-hydroxyphenyl)-retinamide (4-HPR) inhibit the growth of breast cancer cell lines by modulating the insulin-like growth factor I (IGF-I) system?

Conclusion

4-HPR significantly inhibits the growth of both ER+ and ER- breast cancer cell lines by down-regulating the IGF-I system.

Supporting Evidence

  • 4-HPR treatment led to a significant reduction in IGF-I-like protein concentration in both MCF-7 and MDA-MB231 cell lines.
  • Induction of apoptosis was more evident in MCF-7 cells compared to MDA-MB231 cells.
  • 4-HPR inhibited IGF-I stimulated cell proliferation in MCF-7 cells.
  • 4-HPR reduced the levels of IGF-binding proteins in both cancer cell lines.

Takeaway

A substance called 4-HPR can help stop breast cancer cells from growing by messing with a growth system in the cells.

Methodology

The study involved treating breast cancer cell lines with varying concentrations of 4-HPR and measuring cell growth and IGF-I system modulation.

Limitations

The study was conducted in vitro, and results may not fully translate to in vivo conditions.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication